Novanta Inc.
NOVTTechnologyNASDAQScientific & Technical Instruments
Scan Results
Daily timeframeNovanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United. Valued at $5.67B, NOVT is a mid-cap name in its sector. The company operates Automation Enabling Technologies and Medical Solutions segments.
Market Cap
$5.67B
Beta
1.62
P/E (TTM)
114.63
P/E (Fwd)
38.45
EPS (TTM)
$1.39
EPS (Fwd)
$4.14
ROE
5.2%
ROA
4.6%
Cash
$388.8M
Total Debt
$291.3M
Free CF
$87.3M
52W Change
30.7%
Annual Financials
Cash vs Debt
With $388.8M in cash and $291.3M in debt, NOVT maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow comes in at $87.3M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 5.2%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 4.6% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $706.8M (2021) to $980.6M (2025), reflecting a 39% increase over the period.
A beta of 1.62 means NOVT is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. At over 50x earnings, NOVT carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. No single metric tells the full story. Reviewing NOVT's risk profile alongside its fundamentals and technical indicators provides a more complete picture.